BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

...since 2002 when it launched its Criminal Justice Abuse Treatment Studies (CJ-DATS). The goal of CJ-DATS...
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

...P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc. and CJ Group...
...Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cinclus Pharma AG, Basel, Switzerland CJ Group...
BioCentury | Apr 9, 2018
Politics & Policy

Pallone urges CMS drug spending update

House Energy & Commerce Ranking Member Frank Pallone (D-N.J.) is urging CMS to update its Drug Spending Dashboards. According to a letter sent to CMS Administrator Seema Verma on April 6, the agency has not...
BioCentury | Feb 6, 2018
Preclinical News

Wilson reports fatal primate toxicity with second AAV9 variant

...CNS uptake was specific to C57BL/6J mice; its CNS uptake was similar to AAV9 in BALB/cJ...
BioCentury | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

...CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ...
...ATPase is in Phase III development to treat reflux esophagitis and other acid-related gastrointestinal diseases. CJ...
...JASDAQ:4579, Nagoya, Japan) (see BioCentury, Aug. 1, 2011). The partners did not respond to inquiries. CJ Group...
BioCentury | Jun 8, 2015
Clinical News

CJ-12420: Phase III started

...CJ began a double-blind, Korean Phase III trial to compare 100 mg oral CJ-12420 once daily...
...November 2014 deal. In September 2010, RaQualia granted CJ exclusive rights to develop and commercialize CJ-12420...
...include Southeast Asia. CJ Group , Seoul, South Korea RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Product: CJ-12420...
BioCentury | Jan 29, 2015
Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
BioCentury | Dec 18, 2014
Distillery Techniques

Techniques: Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAs

Drug platforms TECHNOLOGY: Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAsMicroRNA-targeted antimiRs conjugated to a peptide with a low pH-induced transmembrane structure (pHLIP) and could help treat solid tumors. The pHLIP is designed to...
BioCentury | Dec 11, 2014
Targets & Mechanisms

PIEZO de resistance

A pair of recently identified calcium channels- PIEZO1 and PIEZO2-control the response of cartilage to heavy loads and offer new targets for joint injury and osteoarthritis, according to findings from a team at Duke University...
BioCentury | Aug 28, 2014
Targets & Mechanisms

A cultured approach to ALS therapy

Although dysfunctional glial cells have long been implicated in amyotrophic lateral sclerosis progression, the precise mechanisms by which they contribute to the disease have remained poorly defined. Now, Harvard University researchers have identified a specific...
Items per page:
1 - 10 of 66
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

...since 2002 when it launched its Criminal Justice Abuse Treatment Studies (CJ-DATS). The goal of CJ-DATS...
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

...P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc. and CJ Group...
...Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Cinclus Pharma AG, Basel, Switzerland CJ Group...
BioCentury | Apr 9, 2018
Politics & Policy

Pallone urges CMS drug spending update

House Energy & Commerce Ranking Member Frank Pallone (D-N.J.) is urging CMS to update its Drug Spending Dashboards. According to a letter sent to CMS Administrator Seema Verma on April 6, the agency has not...
BioCentury | Feb 6, 2018
Preclinical News

Wilson reports fatal primate toxicity with second AAV9 variant

...CNS uptake was specific to C57BL/6J mice; its CNS uptake was similar to AAV9 in BALB/cJ...
BioCentury | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

...CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ...
...ATPase is in Phase III development to treat reflux esophagitis and other acid-related gastrointestinal diseases. CJ...
...JASDAQ:4579, Nagoya, Japan) (see BioCentury, Aug. 1, 2011). The partners did not respond to inquiries. CJ Group...
BioCentury | Jun 8, 2015
Clinical News

CJ-12420: Phase III started

...CJ began a double-blind, Korean Phase III trial to compare 100 mg oral CJ-12420 once daily...
...November 2014 deal. In September 2010, RaQualia granted CJ exclusive rights to develop and commercialize CJ-12420...
...include Southeast Asia. CJ Group , Seoul, South Korea RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Product: CJ-12420...
BioCentury | Jan 29, 2015
Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
BioCentury | Dec 18, 2014
Distillery Techniques

Techniques: Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAs

Drug platforms TECHNOLOGY: Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAsMicroRNA-targeted antimiRs conjugated to a peptide with a low pH-induced transmembrane structure (pHLIP) and could help treat solid tumors. The pHLIP is designed to...
BioCentury | Dec 11, 2014
Targets & Mechanisms

PIEZO de resistance

A pair of recently identified calcium channels- PIEZO1 and PIEZO2-control the response of cartilage to heavy loads and offer new targets for joint injury and osteoarthritis, according to findings from a team at Duke University...
BioCentury | Aug 28, 2014
Targets & Mechanisms

A cultured approach to ALS therapy

Although dysfunctional glial cells have long been implicated in amyotrophic lateral sclerosis progression, the precise mechanisms by which they contribute to the disease have remained poorly defined. Now, Harvard University researchers have identified a specific...
Items per page:
1 - 10 of 66